Stockscreener 앱 받기
2.32
3.57%
0.08
시장 영업 전:
2.35
0.03
+1.29%
전일 마감가:
$2.24
열려 있는:
$2.26
하루 거래량:
1.12M
Relative Volume:
0.80
시가총액:
$131.36M
수익:
-
순이익/손실:
$-44.80M
주가수익비율:
-3.0933
EPS:
-0.75
순현금흐름:
$-30.67M
1주 성능:
+5.45%
1개월 성능:
-64.74%
6개월 성능:
-60.68%
1년 성능:
-40.97%
1일 변동 폭
$2.25
$2.40
1주일 범위
$1.99
$2.40
52주 변동 폭
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
2.32 | 131.36M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 재개 | H.C. Wainwright | Buy |
| 2022-04-27 | 재개 | H.C. Wainwright | Buy |
| 2021-02-08 | 개시 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-10-30 | 개시 | Jefferies | Buy |
| 2020-10-16 | 개시 | BTIG Research | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-12 | 개시 | Oppenheimer | Outperform |
| 2018-12-04 | 개시 | Citigroup | Buy |
| 2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Janney | Buy |
| 2018-01-26 | 개시 | Seaport Global Securities | Buy |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2016-07-01 | 개시 | Stifel | Buy |
| 2015-07-01 | 개시 | Canaccord Genuity | Buy |
| 2015-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2015-03-20 | 재확인 | H.C. Wainwright | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
| 2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
Aldeyra Therapeutics Inc (ALDX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm - GlobeNewswire
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Latest Insider moments: PERCEPTIVE ADVISORS LLC, Aldeyra Therapeutics Inc [ALDX] 10% Owner sold 3,400,000 shares – Knox Daily - knoxdaily.com
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire
Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity - Seeking Alpha
ALDX LEGAL REMINDER: Did Aldeyra Therapeutics, Inc. Commit - GlobeNewswire
ALDX INVESTOR NEWS: Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
ALDX INVESTOR NEWS: Aldeyra Therapeutics, Inc. Investors may be able to Recover Losses in Class Action Investigation -- Contact BFA Law (NASDAQ:ALDX) - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation - markets.businessinsider.com
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
ALDX INVESTOR INVESTIGATION: Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors - citybiz
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors | ALDX Stock News - GuruFocus
30-Year Biotech Leader Chip Clark Strengthens Aldeyra Board: Strategic Move for Pipeline Advancement - Stock Titan
Research Analysts Set Expectations for ALDX Q1 Earnings - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
What is Leerink Partnrs’ Estimate for ALDX Q2 Earnings? - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - markets.businessinsider.com
American Century Companies Inc. Reduces Stock Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra (ALDX) Pre-Earnings Options Activity Signals Potential P - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
ALDX STOCK REMINDER: The Aldeyra Therapeutics, Inc. - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
Aldeyra Therapeutics (NASDAQ:ALDX) Price Target Cut to $9.00 by Analysts at BTIG Research - MarketBeat
ALDX STOCK NOTIFICATION: Did Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Hay Fever Conjunctivitis Therapeutics Market Size in 7MM - openPR.com
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response LetterHagens Berman - The Malaysian Reserve
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on - Bluefield Daily Telegraph
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - markets.businessinsider.com
ALDX CLASS NOTICE: An Investigation has been Initiated on - GlobeNewswire
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA’s Reproxalap Complete Response Letter – Hagens Berman - TradingView
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
ALDX SECURITIES NOTIFICATION: Aldeyra Therapeutics, Inc. Investors that Suffered Losses are Notified to Contact BFA Law - Newsfile
Aldeyra therapeutics sees $4.83 million stock sale by major shareholder - Investing.com South Africa
After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Aldeyra’s Dry Eye Drug Gets Another Rejection from the FDA - Contract Pharma
ALDX SECURITIES REPORT: Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - simplywall.st
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Investors to Inquire about Securities Investigation - markets.businessinsider.com
ALDX SECURITIES NOTICE: Aldeyra Therapeutics, Inc. Investors with Losses are Notified to Contact BFA Law as they may have been Affected by Securities Violations - Newsfile
ALDX SECURITIES ALERT: Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
Aldeyra Therapeutics’ (ALDX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
INVESTOR ALERT: Investigation of Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC - GlobeNewswire
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.00%
자본화:
|
볼륨(24시간):